A Treatment That Improves The Condition Of MS Patients Could Improve The Condition Of This Beaten-Up Biotech
Published on: 16/09/2019
Last year, this biotech firm had a $50 stock and $3 billion market cap. Today, it has a stock trading below $16 and a market cap of just $870 million. But it
Biotech InvestmentsCheap Biotech StocksMarket CapMS TreatmentStock MarketHealth StocksInvestInvestingInvestorsProfitable InvestmentsProfitable StocksStock Market